FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme
– FDA Fast Track Designation for Berubicin highlights the serious unmet medical need for new treatments for glioblastoma multiforme (GBM) – Company recently commenced enrollment in potentially pivotal study evaluating Berubicin in the treatment of adult recurrent glioblastoma multiforme Houston, TX – June 29, 2021 – – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” […]
CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin
IND Approval Marks Key Step in Beginning of Potentially Pivotal Trial of Berubicin HOUSTON (December 17, 2020) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that the Investigational […]
CNS Pharmaceuticals Announces FDA Filing of IND for its Brain Cancer Drug Berubicin
Expects to initiate Phase 2 trial during the first quarter of 2021 Houston, TX – November 17, 2020 – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced that it […]
CNS Pharmaceuticals Announces Appointment of Dr. Patrick Wen, Director of Center for Neuro-Oncology at Dana-Farber Cancer Institute, to Science Advisory Board
Dr. Wen’s appointment bolsters the Company’s neuro-oncology expertise in preparation for upcoming clinical trials of Berubicin in glioblastoma Houston, TX – August 27, 2020) – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central […]
CNS Pharmaceuticals Engages CRO For Phase 2 Berubicin Clinical Trials
Selects Worldwide Clinical Trials as Contract Research Organization Partner Houston, TX – August 20, 2020 – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announced it has engaged Worldwide Clinical […]
CNS Pharmaceuticals Completes Drug Product Manufacturing Strategy for Berubicin
Houston, TX – July 15, 2020 – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today provided an update on the manufacturing strategy for Berubicin drug product, its lead drug candidate for […]
CNS Pharmaceuticals Completes Active Ingredient Shipments to Manufacturers
Houston, TX – July 8, 2020 – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, announced today it has completed shipping its Active Pharma Ingredient (API) to both Maryland based Pharmaceutics International, […]
CNS Pharmaceuticals Announces Filing of FDA Orphan Drug Designation for Brain Cancer Drug Berubicin
Houston, TX – April 23, 2020 – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, today announced it has filed an application with the U.S. Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for its lead product Berubicin. […]
CNS Pharmaceuticals Announces Independent University Research Confirms Active Compound in WP1122 Completely Prevents Coronavirus Replication In Vitro; WP1122 is Subject to Development Agreement with WPD Pharmaceuticals
CNS Pharmaceuticals to receive 50% of net sales on resulting anti-viral commercial products, including WP1122, in certain international markets Houston, TX – April 13, 2020 – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) (“CNS” or the “Company”), a biotechnology company specializing in the development of novel treatments for brain tumors, announced that independent research by the […]
WPD Pharmaceuticals Partners with CNS Pharmaceuticals on Drug Development for Coronavirus and Other Antiviral Indications
Testing of drug candidate WP1122 to be done by leading Government funded research institution specializing in infectious diseases including COVID-19 Vancouver, BC – March 24, 2020 – WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical stage pharmaceutical company, announces it has entered into a development agreement (the “Agreement”) with CNS […]
